ST. LOUIS, May 04, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it will participate in the 37th Annual Heart Rhythm Society (HRS) Scientific Sessions, May 4-7, 2016 in San Francisco. During its 12th consecutive appearance at HRS, the Company will share results of recently published clinical studies, new technology enhancements, user experiences, and simulations of its computer-controlled mapping and lesion formation capabilities at Booth #1631.
“We are excited to bring together expert users of our remote magnetic navigation platform and physicians searching for treatment options that provide improved outcomes for complex cardiac arrhythmias with a lower risk of adverse events and reduced fluoro exposure to patients and physicians,” said William C. Mills, Stereotaxis Chief Executive Officer. “Inspired by an abundance of clinical data and empirical evidence, hospitals and physicians worldwide are turning to our magnetic navigation and automation solutions to strengthen their leadership in cardiac rhythm management by simplifying and significantly enhancing therapy delivery, especially in the complex clinical setting of ventricular arrhythmias.”
In the HRS Rhythm Theatre on Friday, May 6, Stereotaxis will host a lunch symposium featuring the latest insights and clinical research by experienced users. Chaired by Dr. Mauricio Arruda (University Hospitals Case Medical Center), who has completed more than 1,200 procedures using the Niobe® remote magnetic navigation system, the session will provide impressive clinical results of the Niobe system in the treatment of ischemic and non-ischemic ventricular tachycardia (VT) patients, and a discussion of the Company’s multi-center, randomized, superiority study of VT ablation outcomes. Guest speakers include Dr. Luigi Di Biase (Albert Einstein College of Medicine at Montefiore Hospital), Dr. Hiroshi Nakagawa (Oklahoma University Medical Center), and Dr. Tamas Szili-Torok (Erasmus Medical Center).
Dr. Andrea Natale, Executive Medical Director of the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, recently spoke to EP Lab Digest about the value and potential of remote magnetic navigation in electrophysiology for its May issue, which will be available at HRS. In the article, Dr. Natale said, “The people that have actually invested the time to become proficient with remote magnetic navigation and its learning curve, and addressed the differences between magnetic and manual navigation, love this technology and find it difficult when magnetic navigation cannot be used in a procedure.” Dr. Natale is serving as global principal investigator for the Company’s MAGNETIC-VT multi-center randomized study, which he believes could establish remote magnetic navigation as the “gold standard” for certain VT procedures.
In its exhibit space, Stereotaxis will highlight the latest innovations to its Niobe system including the next generation user interface, which includes new features such as improved catheter tip-to-tissue contact confirmation based on bipolar impedance information. During the HRS Rhythm Theatre on Friday, May 6, Dr. Hiroshi Nakagawa will also share the development progress for the lesion assessment and prediction tool called Magnetic Ablation Index. Each of these software features can provide valuable information to physicians while they are ablating tissue and also furthers the ongoing efforts to fully automate the execution of physician-defined ablation strategies. Finally, the Company will unveil its newly developed, software-based simulation platform for physician training, alongside a modeled beating heart phantom that demonstrates the mechanics of its technologies in effective lesion creation – paramount to acute and long-term success – within the most difficult to reach and navigate regions of the heart.
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core Epoch® Solution includes the Niobe® magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management solutions, and the Vdrive® robotic navigation system and consumables.
The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Canada, China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator, V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter advancement system have received clearance in the United States, Canada, and the European Union. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its continued listing on the NASDAQ Capital Market, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.
Company Contact: Martin C. Stammer Chief Financial Officer 314-678-6155 Investor Contact: Todd Kehrli / Jim Byers MKR Group, Inc. 323-468-2300 firstname.lastname@example.org